Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to revolutionize cardiovascular disease prevention and early detection through precision medicine, as highlighted by CEO and Co-Founder Dr. Meesha Dogan in a recent appearance on the BioMedWire Podcast. The company, which leverages epigenetics, genetics, and artificial intelligence, is making strides in both domestic and international markets.
During the podcast, Dr. Dogan detailed Cardio Diagnostics’ expansion into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs. This move aims to bring the company’s AI-powered cardiovascular tests to one of the world’s most populous countries, where heart disease is a leading cause of death. The partnerships are expected to enhance accessibility and personalized care for patients in India.
On the regulatory front, Dr. Dogan provided an update on the Medicare reimbursement process. The company has completed the CPT coding and payment steps, which are critical for reimbursement. However, the coverage determination is still underway, a key milestone that would expand patient access to Cardio Diagnostics’ tests. Successful reimbursement could significantly impact the company’s revenue and adoption rates.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s core technology, the Integrated Genetic-Epigenetic Engine, uses AI to analyze genetic and epigenetic markers to assess cardiovascular risk and guide treatment decisions.
The news matters because cardiovascular disease remains the leading cause of death globally, and early detection is crucial for improving outcomes. Cardio Diagnostics’ approach offers a more precise method for identifying at-risk individuals, potentially reducing healthcare costs and saving lives. The India expansion opens a large market where such technology could have a profound public health impact.
For more details on the podcast, listeners can access the full interview at https://ibn.fm/0VjIz. Updates on the company’s progress are available in its newsroom at https://ibn.fm/CDIO.
Cardio Diagnostics’ focus on precision medicine represents a shift from traditional one-size-fits-all approaches to cardiovascular care. As the company navigates regulatory and commercial hurdles, its success could set a precedent for AI-driven diagnostics in chronic disease management.
